Sign inJoin waitlistJoin the waitlist

John Hays

Associate Director for Clinical Research · Ohio State University Hospital

Credentials: · · · · ·

History

Ohio State University Hospital
Present

Medical Oncology
2008–2010
Internal Medicine
Wake Forest University Baptist Medical Center
2005–2008
Doctor of Medicine
2001–2005

Research

Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses
Journal of the National Cancer Institute · 2014 · 150 citations
Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma
Case report · Molecular Cancer Therapeutics · 2020 · 124 citations
Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target
Oncogene · 2017 · 106 citations

James Chen
13 papers
Anne Noonan
10 papers
David O'Malley
9 papers
Jordan Cloyd
8 papers · 6 as a fellow
Sherif Abdel-Misih
8 papers
Christina Annunziata
7 papers
JL
Jung-Min Lee
6 papers
LM
Lori Minasian
6 papers
Sameek Roychowdhury
6 papers
David Cohn
5 papers
Kristin Bixel
5 papers · 3 as a fellow
Mary Dillhoff
5 papers

Grants

OSU as a Network Lead Academic Participating Site for the NCI NCTN
National Cancer Institute · UG1
Contact PI · $1.1M · Ohio State University
2019–2032
Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $926K · Ohio State University
1997–2025

Clinical trials

Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy
Principal investigator · Terminated · Phase 2
John Hays
2018–2021
Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
Principal investigator · Completed · Phase 2
John Hays
2013–2018
Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
Principal investigator · Completed · Phase 2
John Hays
2012–2022
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
Site PI · Recruiting · Phase 1, Phase 2
GlaxoSmithKline
2025–2028